Structure Based Design of Novel 6,5 Heterobicyclic Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors Leading to The Discovery of Imidazo [1,5-*a*] Pyrazine G-479

Kirk D. Robarge^{a*}, Wendy Lee^a, Charles Eigenbrot^b, Mark Ultsch^b, Christian Wiesmann^b, Robert Heald^c, Steve Price^c, Joanne Hewitt^c, Philip Jackson^c, Pascal Savy^c, Brenda Burton^c, Edna F. Choo^d, Jodie Pang^d, Jason Boggs^d, April Yang^d, Xioaye Yang^d, Matthew Baumgardner^d

^aDiscovery Chemistry, Genentech Inc., 1 DNA Way, South San Francisco California, USA.

^bStructural Biology, Genentech Inc., 1 DNA Way, South San Francisco California, USA.

^cArgenta, Discovery Services Charles River 8-9 Spire Greene Centre, Harlow, Essex, CM 19 5TR, United Kingdom

^dDrug Metabolism and Pharmacokinetics, Genentech Inc., 1 DNA Way, South San Francisco California, USA.

*Corresponding author. Tel.: +1-650-225-2320; fax: +1-650-742-4943; e-mail: kir@gene.com

[Insert Graphical Abstract here]

Abstract: Use of the tools of SBDD including crystallography led to the discovery of novel and potent 6,5 heterobicyclic MEK's.^{1**} The core change from a 5,6 heterobicycle to a 6,5 heterobicycle was driven by the desire for increased structural diversity and aided by the co-crystal structure of **G-925**.^{1**} The key design feature was the shift of the attachment of the five membered heterocyclic ring towards the B ring while maintaining the key hydroxamate and anilino pharamcophoric elements in a remarkably similar position as in **G-925**. From modelling, changing the connection point of the imidazole heterocycle placed the H-bond accepting nitrogen within a good distance and angle to the Ser212.^{1**} The resulting novel 6,5 benzoisothiazole MEKi **G-155** exhibited improved potency versus aza-benzofurans **G-925** and **G-963** but was a potent inhibitor of cytochrome P450's 2C9 and 2C19. Lowering the logD by switching to the more polar imidazo [1,5-*a*] pyridine core significantly diminished 2C9/2C19 inhibition while retaining potency. The imidazo [1,5-*a*] pyridine **G-868** exhibited increased potency versus the starting point for this work (aza-benzofuran **G-925**) leading to deprioritization of the azabenzofurans. The 6,5-imidazo [1,5-*a*] pyridine scaffold was further diversified by incorporating a nitrogen at the 7 position to give the imidazo [1,5-*a*] pyrazine scaffold. The introduction of the C7 nitrogen was driven by the desire to improve metabolic stability by blocking metabolism at the C7 and C8 positions (particularly the HLM stability). It was found that improving on **G-868** (later renamed **GDC-0623**) required combining C7 nitrogen with a diol hydroxamate to give **G-479**. **G-479** with polarity distributed throughout the molecule was improved over **G-868** in many aspects.

Abbreviations

MAPK/ERK kinase (MEK) signaling cascade- The pathway includes many proteins, including MAPK (mitogen-activated protein kinases, originally called ERK, extracellular signal-regulated kinases), which communicate by adding phosphate groups to a neighboring protein, which acts as an "on" or "off" switch. Also known as the RAS-RAF-MEK-ERK mitogen-activated protein kinase signaling pathway; **KRAS-** GTPase KRas also known as V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog and KRAS, is a protein that in humans is encoded by the KRAS gene; **NRAS-** The N-ras oncogene is a member of the Ras gene family and an enzyme that in humans is encoded by the NRAS gene. It was named NRAS for its initial identification in human neuroblastoma cells; **HRAS-** GTPase HRas also known as transforming protein p21 is an enzyme that in humans is encoded by the HRAS gene. Once bound to

guanosine triphosphate, activates a Raf kinase like c-Raf, the next step in the MAPK/ERK signaling cascade; **BRAF**- BRAF is a human gene that makes a protein called B-Raf. The gene is also referred to as proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B, while the protein is more formally known as serine/threonine-protein kinase B-Raf; **RAF**- proto-oncogene serine/threonine-protein kinase also known as c-RAF; **AKT**- AKT is also known as protein kinase B(PKB), is a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription and cell migration; **PI3K**- Phosphatidylinositol-4,5-bisphosphate 3-kinase are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer; **MEKi's**- MAPK/ERK kinase (MEK) signaling cascade inhibitors. A MEK inhibitor is a chemical or drug that inhibits the mitogen-activated protein kinase kinase enzymes MEK1 and/or MEK2. Allosteric MEK inhibitors described herein inhibit both MEK 1 and MEK2; **MEK 1,2 inhibitors** are synonymous with MEKi's; **ATP**- Adenosine triphosphate is a nucleoside triphosphate used in cells as a coenzyme; **H-bond**- Hydrogen bond; **BID**- twice daily; **QD**- once daily; **CYP**- Cytochrome P450; **logD(measured)**- Distribution-coefficient is the ratio of concentrations of a compound in a mixture of two immiscible phases at equilibrium. These coefficients are a measure of the difference in solubility of the compound in these two phases. LogD's have a pH dependence. LogD measurements for MEKi's disclosed herein were performed at pH 7.4; **clogD**- Calculated logD @ pH 7.4; **clogP**- Calculated partition-coefficient (clogP) is the calculated ratio of concentrations of a compound in a mixture of two immiscible phases at equilibrium. These coefficients are a measure of the difference in solubility of the compound in these two phases. The clogP value reflects the overall lipophilicity of a molecule; **IV**- delivered directly into the vein; **PO**- by mouth; **Mic(H/R/M/D/C)**-Microsomes H(human)/R (rat)/M (mouse)/D (dog)/C (cyno). Incubation of the MEKi's described herein was conducted with liver microsomes from human(HLM) and pre-clinical species rat(RLM), mouse(MLM), dog(DLM), and cyno(CLM) to assess comparative metabolic stability; **PEG 400**- polyethylene glycol 400 is a low-molecular-weight grade of polyethylene glycol miscible with water and used as vehicle for dosing rats IV and PO; **CLp**- *In vivo* total plasma clearance is defined as the volume of blood or plasma cleared of drug in a unit time. It is related to the volume in which the drug is dissolved and the rate at which it is eliminated; **T1/2 (hr)**- half life of MEK inhibitor when dosed intravenously; **ppb**- plasma protein binding; **Oral exposure**- Area Under the plasma concentration versus time Curve(AUC); **%F**- oral bioavailability which is the dose-corrected area under curve (AUC) after oral dosing divided by AUC intravenous; **IV/IV -in vitro/ in vivo** clearance correlation (CL predicted from rat microsome incubation/ versus CL observed after intravenous administration in rat)

Keywords

Mitogen-Activated Protein Kinase Kinase Inhibitors

MEK inhibitors

RAS signaling pathway

Imidazo[1,5a] Pyrazine

Imidazo[1,5a] Pyridine

Structure Based Drug Design(SBDD)

Oncology

The MAPK/ERK kinase (MEK) signaling cascade is a key regulator of cellular proliferation, differentiation and survival downstream of RAS activation.² Upregulation of this pathway occurs in a large fraction of tumors, frequently owing to oncogenic activating mutations in KRAS, NRAS, HRAS and BRAF.³ Constitutive activation of the extracellular regulated kinase (ERK) cascade, through oncogenic forms of RAS and mutations in BRAF, has been observed in lung, colon, pancreas, kidney, and ovary primary human tumor samples.⁴ Whereas BRAF inhibitors have shown remarkable efficacy against melanomas with BRAF (V600E) mutations, these compounds are not effective against KRAS-mutant tumors owing to inhibitor-mediated priming of wild-type RAF signaling.⁵⁻⁷ As MEK is

a common effector downstream of wild-type and mutant RAF,^{8,9} MEK inhibitors have the potential to target all tumors dependent on MAPK pathway signaling.

The RAS-RAF-MEK-ERK mitogen-activated protein kinase signaling pathway has emerged as one of the most promising targets for molecularly targeted antitumor agents. Currently, at least twelve MEK inhibitors are at some stage of clinical evaluation for the treatment of cancer (three others have been discontinued) and one has been approved by the FDA for use as a single agent for melanoma (Mekinist™, aka trametinib or GSK 1120212). Many in the field of targeted therapies believe there is greater potential for MEK inhibitors if they are used in combination with other targeted agents such as BRAF¹⁰, AKT¹¹, PI3K inhibitors^{12,13} and immunotherapies¹⁴. Combination therapy has been suggested to better inhibit the MAPK/ERK kinase pathway and therefore prolong treatment effect. The results of phase 1 and 2 clinical studies utilizing a selective BRAF inhibitor, Tafenlar™ (aka dabrafenib), and the selective MEK inhibitor, trametinib, demonstrated the benefit of a combination approach. It was found that dabrafenib and trametinib could be safely combined at 150 mg BID/ 2 mg QD with rare dose-limiting side effects. The combination therapy significantly improved progression free survival and patients showed a higher rate of response in comparison to dabrafenib monotherapy.¹⁰ However, despite the benefit demonstrated by the MEK/BRAF combination, resistance still developed in most patients after an average of 9.4 months. The mechanisms of resistance to combined RAF/MEK inhibition remain poorly understood.¹⁵

MEK 1,2 inhibitors¹⁶ bind to an allosteric binding site proximal to the ATP binding site and as a result are exquisitely selective. These compounds form a tertiary complex with the MEK enzyme and ATP and are ATP noncompetitive.^{17,18} The binding site for allosteric MEK inhibitors has been previously described.^{1**} There are seven structurally related MEK inhibitors in the clinic that all possess an anilino “B-ring” which occupies a lipophilic pocket formed by Leu118, Ile126, Val127, Ile141, Met143, Phe129, Phe209, and Val211 (Fig.1). These MEKi’s all incorporate a halogen at the para position which is lipophilic and polarizable and capable of engaging the carbonyl of Val127 in a halogen bond. Additionally these ATP noncompetitive MEKi’s all have a polar group capable of engaging the terminal phosphate of ATP and Lys97. This polar group is typically a hydroxamate, but other polar functionalities such as an amide, a reverse sulfonamide, or a sulfonyl urea can be utilized. A third binding feature is an H-bond acceptor to Ser212. It has recently been disclosed that certain MEKi’s with superior efficacy against KRAS tumors form a strong H-bond interaction with the Ser212 in MEK that is critical for blocking MEK feedback phosphorylation by wild-type RAF.¹⁹ The strength of the Ser212 H-bond interaction and position relative to the aniline and hydroxamate is determined by the “A-ring” to which these moieties are attached (Fig.1). It has been proposed that increasing the strength of the Ser212/H-bond acceptor interaction results in greater tolerance in the other pharmacophoric elements. A potent MEK inhibitor requires having all three of these binding interactions in place.

[Insert Figure 1 and Figure 1 caption here]

In our search for novel MEK inhibitors, we leveraged key information from the X-ray crystal structure of our previously disclosed 5,6 heterobicyclic azabenzofuran **G-925** to scaffold hop to a new class of 6,5 heterobicyclic MEKi’s^{1**} which, like the 5,6 azabenzofuran, engaged the Ser212 in a monodentate interaction. The scaffold hop from the 6,5 to the 5,6 heterobicyclic scaffold was driven by two factors: 1) increasing the structural diversity and 2) to further our understanding of the influence of the A ring on the placement of the Ser212 H-bond accepting nitrogen and how that impacts potency. Modelling indicated the 6,5 isobenzothiazole **G-155** would be tolerated in the MEK binding pocket with the H-bond accepting nitrogen capable of making a good interaction with Ser212. As shown in Figure 2, the 6,5 heterobicyclic isobenzothiazole **G-155**, while equipotent in the

biochemical assay showed increased potency versus its azabenzofuran comparator **G-963** in both cell proliferation assays. Typically for our potent MEKi's, the biochemical assay was not as useful as the 72h cell proliferation assays for differentiation. The cell proliferation (particularly the HCT116 cell proliferation assay) potency was the decision making potency readout used to differentiate our potent MEKi's and determine their progression.

[Insert Figure 2 and Figure 2 caption here]

Although isobenzothiazole **G-155** was potent, progression was halted due to potent 2C9/2C19 CYP inhibition (Table 1). It was reasoned that the CYP 2C9/2C19 inhibition could be reduced by lowering lipophilicity and logD. A decision was made to introduce polarity into the core and scaffold hop to 6,5 imidazo [1,5-*a*] pyridines. In addition to lowering the lipophilicity (reflected in the *measured* logD @ pH 7.4) versus the isobenzothiazole, the imidazo[1,5-*a*] pyridine core increased the structural diversity of the 6,5 heterobicyclic MEKi's and differentiated the pKa's (cpKa's using MOKA1.1.0 for **G-155/G-868**= 1.83/4.78) which can effect the strength of the H-bond interaction with Ser212. Both imidazo [1,5-*a*] pyridines **G-868**^{20,21} and **G-606**²² retained cell proliferation potency and exhibited greatly reduced 2C9(warfarin) /2C19 (mephenytoin) inhibition (Table 1). Imidazo [1,5-*a*] pyridines **G-868** and **G-606** did not inhibit cytochrome P450's 3A4 (testosterone/midazolam), 2D6 (dextromethorphan) and 1A2 (phenacetin). With three examples of 6,5 heterobicyclic MEKi's with increased potency versus their direct aza-benzofuran comparator (**G-963**), the 5,6 aza-benzofuran core was deprioritized.

[Insert Table 1 and Table 1 caption here]

The potency of the 6,5 heterobicyclic MEKi's indicate the positioning of the pharmacophore elements, including the Ser212 H-bond acceptor nitrogen, are well tolerated in the MEK binding pocket. The polar functionality (A-ring dependent) are positioned optimally as shown by the X-ray co-crystal structures in Figure 3.

[Insert Figure 3 and Figure 3 caption here]

The imidazopyridine class of MEKi's replaced the benzoisothiazoles with the 5-imidazo [1,5-*a*] pyridines preferred versus the 8-imidazo [1,5-*a*] pyridines. **G-868** was chosen as our new lead. **G-868** exhibited improved predicted metabolic stability in dog and cyno microsomes, low total CL *in vivo*, longer IV half life, higher AUC and %F versus the its direct comparator 8-imidazo[1,5-*a*] pyridine **G-606** (Table2). The **G-868/G-606** comparison and conclusion is representative of the bigger data set of 5-imidazo versus 8-imidazo [1,5-*a*] pyridines. Note that both the 5 and 8- imidazo [1,5-*a*] pyridines inhibit the hERG channel.

[Insert Table 2 and Table 2 caption here]

For the 5-imidazo [1,5-*a*] pyridines we observed poor *in vitro/in vivo* CL correlation (IV/IV, see Supplemental Material) in rat and **G-868** was no exception. Despite efforts to understand the IV/IV disconnect, a satisfactory explanation was elusive and a decision was made to put more weight on *in vivo* studies in rat. Our qualitative met ID studies indicated **G-868** was stable in rat (82%). Some metabolism occurred on the hydroxamate (10% acid, 5% amide, see Supplemental Material; in mouse there is some turnover -NADPH, which appears to be hydrolysis to the acid and accounts for 1.2% of total). Even though our met ID data did not indicate C8 as a site of metabolism,

Metasite^{TM 23,24} did. Thus, **G-879** (HCT116 IC₅₀ = 0.14 μ M), containing a C8-fluorine was synthesized. From a cell proliferation potency standpoint, the C8 fluorine was not detrimental to potency. However, consistent with the Metasite analysis, C8 fluorine incorporation lowered *in vivo* CLp, increased half life and oral exposure in rat, consistent with blocking a site of metabolism. Unfortunately CYP2C9 inhibition activity for **G-879** increased sevenfold.

[Insert Figure 4 and Figure 4 caption here]

Encouraged it was possible to reduce total and free drug clearance (**G-879** ppb rat = 97%, free drug CL = 55 mL/min/kg vs. 1320 mL/min/kg for **G-868**, ppb rat = 99%), increase T_{1/2} and oral exposure by blocking C8, a second Metasite analysis (Figure 5) indicated that incorporation of a nitrogen at C7 would block metabolism at both C7 and C8 (Figure 5). Incorporation of a nitrogen at C7 of the imidazo [1,5-*a*] pyridine core was also anticipated to have additional benefits by lowering the cLogP/cLogD and decreasing the pKa for the imidazo [1,5-*a*] pyrazines. Decreasing lipophilicity along with decreasing basicity would increase the probability of improving the hERG IC₅₀ versus **G-868**. Based on met ID data, the hydroxamate was the major metabolic site of **G-868** and one way to modulate clearance would be to make the hydroxamate less prone to hydrolysis. However, it was difficult to predict *a priori* how the N7 nitrogen and lower lipophilicity would effect the metabolism of the hydroxamate. **G-593** was synthesized to determine if an imidazo [1,5-*a*] pyrazine could further improve on the imidazo [1,5-*a*] pyridine **G-868**.

[Insert Figure 5 and Figure 5 caption here]

As shown in Table 3, the incorporation of a nitrogen at C7 (**G-593**) lowered the cLogP/cLogD versus **G-868**. Both MOKA and the ACD software predicted a lower pKa, though the magnitude of decrease is different. The measured pKa's validated the predictions as the pKa for **G-593** is two units lower versus **G-868**. However, despite the lower cLogP/cLogD and decreased pKa, there is no change in the hERG IC₅₀. The *measured* logD (@ pH 7.4) shows identical values for **G-868** and **G-593**, a possible reason for lack of improvement in the hERG IC₅₀. That the overall hydrophobicity, as reflected in logD measurements, is identical may reflect "buried" polar surface area in **G-593** if the hydroxamate NH is engaged in an H-bonding interaction with N7. Such an interaction may not be reflected in the logD. The working hypothesis that came out of this result was that for the imidazo [1,5-*a*] pyridine MEKi's (Table 3) any improvement in hERG IC₅₀ is likely to be driven by decreased lipophilicity (i.e. lowering *measured* logD). The imidazole nitrogen in **G-868** is not very basic to begin with (pKa 4.30), so lowering its pKa does not impact the hERG IC₅₀.

[Insert Table 3 and Table 3 caption here]

[Insert Figure 6 and Figure 6 caption here]

Though the anticipated improvement in hERG IC₅₀ was not realized, further exploration of the imidazo [1,5-*a*] pyrazines was conducted. As shown in Table 4, the cell proliferation potency lost by the addition of a nitrogen at the 7 position could be regained with a more hydrophobic side chain without increasing the logD (**G-593** vs. **G-327**). **G-593** and **G-327** exhibited higher total CL and lower exposure than **G-868**. However, unlike the imidazo [1,5-*a*] pyridine class of MEKi's, the *in vivo* clearance was in line with that predicted from *in vitro* RLM stabilities. The lower total clearance exhibited by **G-868** may be due in part to its high plasma protein binding. *The most pronounced effect of the N7 modification was decreasing plasma protein binding.* Plasma protein binding

was decreased across species (3-9%, 7% lower in rat). The nitrogen in **G-593** increased metabolic stability and so lowered the unbound clearance (**G-593** 600 mL/min/kg versus **G-868** 1320 mL/min/kg; ppb (rat) **G-868**= 99%, **G-593** = 92%). Permeability in the A-B direction increased for **G-593** with reduced efflux (B-A/A-B = 0.7 vs. 2.60 for **GDC-868**).The improved permeability may be a result of an effective decrease in polar surface area due to the hydroxamate NH engaging in an H-bonding interaction with N7. While such an interaction may not be reflected in the logD it could result in improved permeability. Lowering of the plasma protein binding resulting in a lowering of the free drug clearance and improved permeability demonstrated C7 nitrogen modification could influence drug like properties in a positive way.

Encouraged by the improved permeability and the decreased free drug clearance we revisited our working hypothesis that we could improve the hERG IC₅₀ by lowering logD. It was reasoned that adding a more polar hydroxamate side chain would lower the logD. Additionally, spreading polarity throughout the molecule is one strategy that has been utilized to improve hERG by destabilizing the interaction with the lipophilic cavity of the hERG channel.²⁵ Our microsome stability calculations indicated improvement in metabolic stability across species with the additional polarity. Incorporation of the diol hydroxamate sidechain in **G-479** lowered the *measured* LogD and an improvement in the hERG IC₅₀ was realized (Table 4). As predicted by *in vitro* RLM's (the pyrazines exhibited an excellent IV/IV correlation for rat), **G-479** exhibited improved metabolic stability in rat, lower plasma protein binding across species, improved MDCK permeability (less efflux), lower free drug CL (92 mL/min/kg vs 1300 mL/min/kg for **G-868**), and increased LLE (Supplemental Material) compared with **G-868**. The *in vivo* total CLp in rat was equivalent to **G-868**, the exposure and %F much improved versus **G-593** and **G-327**. The oral exposure of **G-479** was only two fold lower than that of the lead imidazo [1,5-*a*] pyridine **G-868**. Since the secondary hydroxyl of the diol hydroxamate had no effect on cell proliferation potency (**G-593** 120 nM vs. **G-479** 107 nM), the potency loss suffered by **G-479** can be rationalized by a weaker interaction with the Ser212 nitrogen due to the less basic H-bond accepting nitrogen.

[Insert Table 4 and Table 4 caption here]

The imidazo[1,5-*a*]pyrazines were synthesized by the following 10 step synthetic route.

[Insert Scheme1 and Scheme 1 caption here]

Some interesting features of the chemistry included the following:

- (a) The reaction did not work at all using LDA obtained from commercial sources. It was necessary to freshly prepare the LDA to obtain **2**. (b) In the conversion of **2** to **3**, if LDA was used as the base it was prepared fresh since that was considered best practice. However, commercial LHDMS (Aldrich) could be used as the base with comparable yields.
- (e) In the synthesis of **G-868** the reduction of the nitrile to the benzyl amine was accomplished in good yield by a CoCl₂/ NaBH₄/ MeOH reduction.^{20,21} Applying the same procedure to **5** gave no product. In the case of pyrazine **5**, the major product isolated from the CoCl₂/NaBH₄ mediated reduction of **5** was the 2-F 4-TMS aniline. This result necessitated the screening of several reduction conditions to find one that cleanly transformed **5** into **6**. It was

found that it was absolutely necessary to run the hydrogenation reaction in glacial acetic acid to achieve a high yield of crude **6** (presumably the acetate salt) which was of suitable purity to be taken on directly. This result also indicated the imidazo [1,5-*a*] pyrazine core is stable under acidic but not basic reaction conditions

(e)-(h) Crude material was carried through steps (e)-(h) and purification performed on intermediate **9**

(i) It was necessary to hydrolyze the ester using tin mediated hydrolysis conditions at 85°C³⁵ as the more standard hydrolysis conditions of LiOH/ THF/MeOH/ H₂O resulted in decarboxylation. This result was consistent the previous observation that the imidazo [1,5-*a*] pyrazine core was stable under acidic reaction conditions (even with heating to 85°C!!) but not basic reaction conditions.

(j) Changing the base from DIPEA to 4-methylmorpholine improved the yield of the coupling reaction 4.5 fold (11% to 50%)

In planning for success and scalability, there was precedent in the MEK patent literature for hydroxamate formation directly from the ester (74% yield on a 200 g scale).³⁹ While the imidazo [1,5a] pyrazines were prepared on 50-200 mg scale with the final step being an EDCI/HOBT coupling, we did also explore hydroxamate formation directly from the methyl ester(Fig. 10). When preparing the hydroxamate from the methyl ester, it was critical to use three equivalents of the LHMDs base. Two representative examples are shown below.

[Insert Scheme 2 and Scheme 2 caption here]

A plot of the biochemical potency versus LogD and cLog P (overall hydrophobicity) can be found in the Supplemental Material. Both the LLE vs. measured LogD and calculated cLogP plots show a progression of the 6,5 heterobicyclic MEKis towards greater LLE. Imidazo [1,5-*a*] pyrazine **G-479** gained 1.5 units in LLE and is the most ligand efficient 6,5 heterobicycle described in this manuscript.

Leveraging X-ray crystal structure data for **G-925** gave rise to novel 6,5-heterobicyclic cores. The starting point for this work was the novel 6,5 heterobicyclic isobenzothiazole MEKi which interacted with Ser212 in a monodentate fashion as did **G-925** but exhibited increased cell proliferation potency.^{1**} Unfortunately isobenzothiazole **G-155** was a potent 2C9/2C19 inhibitor which prompted a core change to a more polar 6,5 heterobicyclic core. The imidazo [1,5-*a*] pyridine core with lower lipophilicity eliminated 2C9/2C19 inhibition and increased structural diversity. A new 6,5 heterobicyclic lead emerged, the imidazo [1,5-*a*] pyridine **G-868**²⁰. **G-868** went on to become a clinical candidate and was later renamed **GDC-0623**.^{19,21} The 6,5-imidazo [1,5-*a*] pyridine scaffold was further optimized by incorporating a nitrogen at the 7 position to yield the 6,5-heterobicyclic imidazo [1,5-*a*] pyrazine core. The introduction of the C7 nitrogen was driven by increasing the structural diversity of the 6,5 heterobicycles while also adding polarity in a position where potency would be retained and metabolic stability improved. Even though *in vivo* met ID data did not lead us down this road, testing a hypothesis based on a MetaSite prediction resulted in the discovery of a fourth novel and potent 6,5 heterobicyclic scaffold, the imidazo [1,5-*a*] pyrazines. The nitrogen at the 7 position did not result in an improvement in hERG IC₅₀ as expected. The learning here was that lowering the lipophilicity (as reflected in lowering the LogD) is more important for improving hERG than pKa. The N7 modification did have an effect on physicochemical properties by reducing the plasma protein binding across species. The nitrogen increased metabolic stability and so lowered the unbound clearance . A nitrogen at C7 was not sufficient in itself to improve upon the oral exposure of **G-868 (GDC-0623)**. Combining N7 with a diol hydroxamate which spread the polarity throughout the molecule gave imidazo [1,5-

α]pyrazine **G-479** which was improved over **G-868 (GDC-0623)** in many aspects (e.g., hERG, lower ppb across species, 14x lower free drug CL, improved (H/R/M) microsome stability and passive permeability, Table 4). The LLE analyses done retrospectively (Supplemental Material) demonstrates the progression of novel 6,5-heterobicycles towards increased LLE after moving away from the 5,6-aza-benzofuran scaffold.

The core change to the 6,5 heterobicyclic scaffold was potency driven and once discovered further diversified to give additional novel and potent 6,5 heterobicyclic MEKis. **G-479** did improve on **G-868 (GDC-0623)** in many aspects but due to the two fold potency loss in HCT116 cell proliferation assay coupled with the two fold lower oral exposure, **G-479** was not able to displace **G-868 (GDC-0623)** as the development candidate.

This work is yet another example in the medicinal chemistry literature where small structural changes can have big consequences. The 6,5 heterobicycles were enabled by the crystal structure of the 5,6 aza-benzofuran **G-925**.^{1**} Once the discovery of the first 6,5-heterobicyclic core was made, it offered an opportunity to utilize a successful medicinal chemistry strategy (especially for kinase inhibitors) of incorporating nitrogen atoms in specific places to add polarity, increase structural diversity, improve potency, PK, and properties and give rise to novel MEKi scaffolds. Use of the predictive tool MetaSite was rewarded by the discovery of imidazo [1,5- α]pyrazine **G-479**. The design strategy taken was a successful one as demonstrated by the discovery of clinical candidate **GDC-0623** which has progressed to phase 1b.

Acknowledgments

The authors gratefully thank the purification and analytical groups within Genentech Small Molecule Drug Discovery for their support. We also thank Dr Joseph Lyssikatos for helpful discussions and encouragement in making the hydroxamate directly from the methyl ester as described in the patent literature, Dr. Mark Zak for his suggestion to try the trimethyl tin mediated hydrolysis of **9** after the more conventional hydrolysis procedure unexpectedly gave exclusively the decarboxylation product. Dr. Mark Zak and Dr. Anthony Estrada provided helpful discussions on the experimental details of the methyl ester hydrolysis. We acknowledge the use of synchrotron X-ray sources at APS (Advanced Photo Source-Argonne National Laboratory, outside Chicago IL) and SSRL (Stanford Synchrotron Radiation Lightsource, Palo Alto CA) supported by the Department of Energy's (DOE) Office of Science. The SSRL Structural Molecular Biology Program is also supported by DOE's Office of Biological and Environmental Research, and by the National Institutes of Health (NIH). Refinement statistics for the structures in Figure 3 are summarized in the Supplementary Material.

References and Notes

1. Heald, R.A.; Jackson, P.; Savy, P.; Jones, M.; Gancia, E.; Burton, B.; Newman, R.; Boggs, J.; Chan, E.; Chan, J., Choo, E. Merchant, M.; Rudewicz, P.; Ultsch, M.; Weismann, C.; Yue, Q.; Belvin, M.; Price, S. *J. Med. Chem.* **2012**, *55*, 4594. ** A reading of ref. 1 is recommended for key background information, the genesis of the 5,6 scaffolds and the origin and significance of isobenzothiazole **G-155** which is used as the starting point for the **G-479** discovery.
2. Downward, J. *Nature Rev. Cancer* **2003**, *3*, 11.
3. Bamford, S.; Dawson, E.; Forbes, S.; Clements, J.; Pettett, R.; Dogan, A.; Flanagan, A.; Teague, J.; Futreal, P.A.; Stratton, M.R.; Wooster, R. *Br. J. Cancer* **2004**, *91*, 355.

4. Hoshino, R.; Chantani, Y.; Yamori, T.; Tsuruo, T.; Oka, H.; Yoshida, O.; Shimada, Y.; Ari-I, S.; Wada, H.; Fujimoto, J.; Kohno, M. *Oncogene* **1999**, *18*, 813.
5. Hatzivassiliou, G.; Song, K.; Yen, I. Brandhuber, B.J.; Anderson, D.J.; Alvarado, R.; Ludlam, M.J.; Stokoe, D.; Gloor, S.L.; Vigers, G.; Morales, T.; Aliagas, I.; Liu, B.; Sideris, S.; Hoeflich, K.P.; Jaiswal, B.S.; Seshagiri, S.; Koeppen, H.; Belvin, M.; Friedman, L.S.; Malek S. *Nature* **2010**, *464*, 431.
6. Heidorn, S. J.; Milagre, C.; Whittaker, S.; Nourry, A.; Niculescu-Divas, I.; Dhomen, N.; Hussain, J.; Reis-Filo, J.S.; Springer, C.J.; Pritchard, C.; Marais, R. *Cell* **2010**, *140*, 209.
7. Poulikakos, P. I.; Zhang, C.; Bollag, G.; Shokat, K. M.; Rosen, N. *Nature* **2010**, *464*, 427.
8. Solit, D. B.; Garraway, L.A.; Pratilas, C.A.; Sawai, A.; Getz, G.; Basso, A.; Ye, Q.; Lobo, J.M.; She, Y.; Osman, I.; Golub, T.R.; Sebolt-Leopold, J.; Sellers, W.R.; Rosen, N. *Nature* **2006**, *439*, 358.
9. Wellbrock, C.; Karasarides, M.; Marais, R. *Nature Rev. Mol. Cell Biol.* **2004**, *5*, 875.
10. Flaherty, K.T.; Infante, J.R.; Daud, A.; Gonzalez, R.; Kefford, R.F.; Sosman, J.; Hamid, O.; Schuchter, L.; Cebon, J.; Ibrahim, N.; Kaduchadkar, R.; Burris, H.A. III; Falchook, G.; Algazi, A.; Lewis, K.; Long, G.V.; Puzanov, I.; Lebowitz, P.; Singh, A.; Little, S.; Sung, P.; Allred, A.; Ouellet, D.; Kim, K.B.; Patel, K.; Weber, J. *N. Engl. J. Med.* **2012**, *367*, 1694.
11. Clinical Trials.gov NCT01138085 Safety, PK of AKT and MEK Combination (GSK1120212 and GSK2141795) Currently recruiting patients.
12. Haagenzen, E.J.; Kyle, S.; Beale, G.S.; Maxwell, R.J.; Newell, D.R. *British Journal of Cancer* **2012**, *106*, 1386.
13. Shimizu, T.; Tolcher, A.W.; Papadopoulos, K.P.; Beeram, M.; Rasco, D.W.; Smith, L.S.; Gunn, S.; Smetzer, L.; Mays, T.A.; Kaiser, B.; Wick, M.J.; Alvarez, C.; Cavazos, A.; Mangold, G.L.; Paitnaik, A. *Clin. Cancer Res* **2012**, *18*; 2316
14. Menzies, A.M.; Long, G.V. *Ther Adv Med Oncol.* **2013**, *5*; 278.
15. Wagle, N.; Van Allen, E.M.; Treacy, D.J.; Frederick, D.T.; Cooper, Z.A.; Taylor-Weiner, A.; Rosenberg, M.; Goetz, E.M.; Sullivan, R.J.; Farlow, D.N.; Friedrich, D.C.; Anderka, K.; Perrin, D.; Johannessen, C.M.; McKenna, A.; Cibulskis, K.; Kryukov, G.; Hodis, E.; Lawrence, D.P.; Fisher, S.; Getz, G.; Gabriel, S.B.; Carter, S.L.; Flaherty, K.T.; Wargo, J.A.; Garraway, L.A. *Cancer Discov*; **2014**, *4*, 61.
16. Price, S. *Expert Opin. Ther. Pat.* **2008**, *18*, 603.
17. Ohren, J. F.; Chen, H.; Pavlovsky, A.; Whitehead, C.; Zhang, E.; Kuffa, P.; Yan, C.; McConnell, P.; Spessard, C.; Banotai, C.; Mueller, W. T.; Delaney, A.; Omer, C.; Sebolt-Leopold, J. S.; Dudley, D. T.; Leung, I. K.; Flamme, C.; Warmus, J.; Kaufman, M.; Barrett, S.; Tecle, H.; Hasemann, C. A. *Nature Struct. Mol. Biol.* **2004**, *11*, 1192.
18. Fischmann, T. O.; Smith, C. K.; Mayhood, T. W.; Myers, J. E., Jr.; Reichert, P.; Mannarino, A.; Carr, D.; Zhu, H.; Wong, J.; Yang, R.; Le, H. V.; Madison, V. S. *Biochemistry* **2009**, *48*, 2661.
19. Hatzivassiliou, G.; Haling, J.R.; Chen, H.; Song, K.; Price, S.; Heald, R.; Hewitt, J.F.M.; Zak, M.; Peck, A.; Orr, C.;

Merchant, M.; Hoeflich, K.P.; Chan, J.; Luoh, S.-M.; Anderson, D.J.; Ludlam, M.J.C; Wiesmann, C.; Ultsch, M.; Friedman, L.S.; Malek, S., Belvin, M. *Nature* **2013**, 501, 232.

20. **G-868** appeared in the patent literature in 2009: Price, S.; Heald, R.; Lee, W.; Zak, M. E.; Hewitt, J.; Frances M.; **2009** WO 85983 A1.
21. For the first public disclosure of the structure of **GDC-0623**, see Supplemental Material in reference 19.
22. **G-606** appeared in the patent literature in 2009: Price, S.; Heald, R.; Savy, P.P.A.; **2009** WO 85980 A1.
23. Caron, G.; Ermondi G.; Testa, B. *Pharm Res.* **2007**, 24, 480.
24. See also <http://www.moldiscovery.com/publications.php> MetaSite.
25. Jamieson, C.; Moir, E.M.; Rankovic, Z.; Wishart, G. *J. Med Chem.* **2006**, 49, 5029.
26. Heald, R. A.; Jackson, P.; Lyssikatos, J.; Price, Stephen; Savy, P.P. WO2010/3025A1, 2010
27. All reactions except (e) were run in oven dried glassware cooled under N₂, under an atmosphere of N₂.

Reagents were used as received from commercial sources without any additional purification.
28. The preparation of 2-fluoro-4-(trimethylsilyl)aniline, was first disclosed in: Goutopolis, A.; Askew, B.C. Jr.; Chen, X.; Srinivasa, K.; Yu. H. **2007** WO123936 A1. See also Price, S.; Heald, R. Lee, W.; Zak, M.E.; Hewitt, J. Frances M.; **2009** WO 85983 A1; **2010** WO3025A1; **2010** WO3022A1; **2009** WO93013A1.
29. A fresh bottle of anhydrous DMF was degassed by sparging with nitrogen for 2h prior to the running of the cyanation reaction.
30. Prior to adding the 10% Pd-C catalyst, the round bottomed flask was evacuated under house vacuum and filled with nitrogen 3X.
31. Reaction times longer than 1.5h (i.e., 3h) resulted in over-reduction products being formed .
32. Conc. = 0.16M, and a suspension resulted .The reaction mixture to form **(7)** never became homogeneous.
33. After extractive workup (EtOAc., sat'd NaHCO₃/ water/ brine wash, Na₂SO₄ drying), crude pdt. **(7)** was azeotroped with DCM to give an orange foam of suitable purity by LC/MS to be used directly without purification for the next step.
34. After extractive workup (EtOAc., sat'd NaHCO₃/ water/ brine wash, Na₂SO₄ drying), crude pdt. **(8)** was azeotroped with DCM to give a yellow solid of suitable purity to be carried on directly to the next step.
35. Nicolaou, K.C.; Zak, M.; Safina, B.S.; Estrada, A.A.; Lee, S.H.; Nevalainen, M. *J. Am. Chem. Soc.* **2005**, 127, 11176.

36. After extractive workup (EtOAc., 1M HCl(3x)/ water/ brine wash, Na₂SO₄ drying), the crude product **(10)** was treated with DCM/Et₂O/hexane. Crystals resulted which were collected by suction filtration and dried under house vacuum and used in the hydroxamate coupling reactions
37. Crude **G-327** was purified by SiO₂ chromatography (ISCO, 65-100%EA/hex, followed by 0-50% MeOH/EA.) and the resulting viscous oil treated with DCM (1 drop)/ ether/hexane to afford a yellow solid. The ether / hexane/ DCM solution from which the yellow solid precipitated was removed from the round bottomed flask via pipette, transferred to a second round bottomed flask and concentrated. The resulting oil was purified by prep HPLC to give additional **G-327** of > 98% purity. The yellow solid that had precipitated after treatment with DCM (1 drop)/ ether/ hexane precipitate was dried under high vacuum overnight .
38. Crude hydroxamate was purified by SiO₂ chromatography (ISCO, 0-10% MeOH/DCM). **G-573** and **G-479** were crystallized from DCM/ ether/hexane. Collected yellow solid via filtration and dried under high vacuum overnight.
39. Marlow, A. L.; Wallace, E.; Seo, J.; Lyssikatos, J.P.; Yang, H. W.; Blake, J.; Storey, R. A.; Booth, R. J.; Pittam, J. D.;Leonard, J. *et al* **2007** WO044084 A2 20070419.

Supplemental Material

IV/IVc = *in vitro*/ *in vivo* clearance correlation (CL predicted from rat liver microsome incubation on X-axis / versus total CL observed after intravenous administration on the Y-axis) for the imidazo[1,5-*a*] pyridines.

G-868 (MEK) In Vivo rat plasma

Objective: To identify metabolites of G-868 in plasma from rats dosed PO (5mg/kg) study No 07-1276.

Method: Metabolite ID was done with the 5, 15, 30, 60, 120 7 240 minute time points combined & extracted with acetonitrile. The supernatant was dried to a small volume to remove most of the acetonitrile.

Conclusion: Under the current experimental conditions seven metabolites were identified. Most of the metabolism takes place at the N-(2-hydroxyethoxy)amide side chain with the free acid (M7) being the most significant metabolite.

Proposed Metabolic Profile

*Percent is normalized against the sum area counts

Other peaks shown are not drug related

Lipophilic Ligand Efficiency (logD vs. pKi and cLogP vs. pKi for MEKi's)

Retrospective LLE analysis. Biochemical potency versus measured LogD is plotted for the compounds described in this manuscript and reference compounds (**Mekinist™** the sole marketed MEKi, **AZD6244**, **GDC-0973** two MEKi's in clinical studies and the **PD-901** the first biaryl anilino scaffold disclosed which served as a starting point for many MEKi programs). It should be noted that the pKa of **GDC-0973** is 8.5 which results in a lowering of the LogD. It is the combination of this lower LogD and high pKa that results in the high LLE rather than **GDC-0973** having particularly great LLE. All of the other MEKi's included in this plot won't be ionized at neutral pH.

Retrospective LLE analysis. Biochemical potency versus measured cLogP (overall hydrophobicity) is plotted since measured logD takes into account charge and in doing so raises the possibility of overstating the LLE of charged compounds such as **GDC-0973** which shifts 2.5 LLE units to the right when cLogP is utilized versus cLogD. The other MEKi's are neutral species at pH 7.4 and as expected do not shift. With the x axis = cLogP, again there is a progression of the 6,5 bicyclic heterocyclic MEKi's towards greater LLE.

X-RAY TABLES

Table 1. Data Collection and Refinement for G-805 and G-799 Complexes

	MEK1/G-805	MEK1/G -799
<u>Data collection</u>		
space group	SSRL 11-1	ALS 5.0.2
unit cell (Å,°)	P6 ₂	P6 ₂
	<i>a</i> = 81.845, <i>b</i> = 81.845,	<i>a</i> =81.899, <i>b</i> =81.899,
	<i>c</i> = 129.604	<i>c</i> =129.24
V _M (Å ³ /Dalton)	3.29	3.29
Resolution (Å)	50 – 2.7 (2.8 – 2.7)	50 – 2.8 (2.9 – 2.8)
R _{sym} ^{a,b}	0.08 (0.588)	0.068 (0.542)
Number of observations	20826	61815
Unique reflections	12041	12111
Completeness (%) ^b	99.9 (99.7)	99.9 (100)
I/σI ^b	17.9 (1.19)	20.8 (2.75)
Wilson B (Å ²)	76.3	71.2
<u>Refinement</u>		
Resolution (Å)	20 – 2.7	20 – 2.8

Number of reflections	12037	12105
($F > 0\sigma(F)$)	1.39	1.36
Final R^c , R_{FREE}	0.161, 0.214	0.164, 0.224
Molecules/asymmetric unit	1	1
protein residues	291	286
water/ions/ligands	11/ 1/ 2	13/ 1/ 2
atoms	2349	2317
Mean B-factor ($\text{\AA}^2$) ^d	70/60/70	67/58/67
Rmsd bonds ($\text{\AA}$)	0.009	0.009
Rmsd angles ($^\circ$)	1.25	1.38
Number of TLS groups	4	3
Ramachandran (%)	94.0/4.5/0.7/0.0	95.7/3.6/0.7/0.0

^a $R_{\text{sym}} = \sum |I| - | \langle I \rangle | / \sum | \langle I \rangle |$, where I is the intensity of a single observation and $\langle I \rangle$ the average intensity for symmetry equivalent observations.

^b In parenthesis, for the highest resolution shell.

^c $R = \sum |F_o - F_c| / \sum |F_o|$, where F_o and F_c are observed and calculated structure factor amplitudes, respectively. R_{FREE} is calculated as R for reflections sequestered from refinement.

^d protein/ ligand/ all atoms

Table 2. Data Collection and Refinement for G-659 Complex

	MEK1/G-659
<u>Data collection</u>	ALS 5.0.1
space group	P6 ₂
unit cell ($\text{\AA}$, $^\circ$)	$a = 82.083$, $b = 82.083$, $c = 129.48$
V_M ($\text{\AA}^3/\text{Dalton}$)	3.29
Resolution ($\text{\AA}$)	30 – 2.6 (2.7 – 2.6)
$R_{\text{sym}}^{\text{a,b}}$	0.078 (0.752)
Number of observations	87074
Unique reflections	13584
Completeness (%) ^b	99.9 (100)
$I/\sigma I^b$	30.2 (2.25)
Wilson B ($\text{\AA}^2$)	56.95
<u>Refinement</u>	
Resolution ($\text{\AA}$)	20 – 2.7
Number of reflections	13579
($F > 0\sigma(F)$)	1.35
Final R^c , R_{FREE}	0.167, 0.218
Molecules/asymmetric unit	1
protein residues	289
water/ions/ligands	35/ 1/ 2
atoms	2359
Mean B-factor ($\text{\AA}^2$) ^d	60/44/60
Rmsd bonds ($\text{\AA}$)	0.008
Rmsd angles ($^\circ$)	1.17
Number of TLS groups	4

Ramachandran (%) 95.7/3.5/0.7/0.0

^a $R_{\text{sym}} = \frac{\sum ||I| - \langle I \rangle||}{\sum \langle I \rangle}$, where I is the intensity of a single observation and $\langle I \rangle$ the average intensity for symmetry equivalent observations.

^b In parenthesis, for the highest resolution shell.

^c $R = \frac{\sum |F_o - F_c|}{\sum |F_o|}$, where F_o and F_c are observed and calculated structure factor amplitudes, respectively. R_{FREE} is calculated as R for reflections sequestered from refinement.

^d protein/ ligand/ all atoms

Use of the Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, is supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract No. DE-AC02-76SF00515.

The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research, and by the National Institutes of Health, National Institute

of General Medical Sciences (including P41GM103393). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of NIGMS or NIH.

Use of the Advanced Photon Source was supported by the U. S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357.

Table 1.

	G-963	G-155	G-868 5-imidazopyridine	G-606 8- imidazopyridine
Cell Proliferation EC ₅₀ (μM)				
HCT116	0.120	0.044	0.051	0.035
A3750	0.025	0.007	0.004	0.002
clogP	3.1	3.6	2.3	2.3
LogD	3.1	3.1	2.1	2.1
2C9/2C19 IC ₅₀ (μM)	>10/>10	1.3/1.8	>10/>10	7.3/16
3A4t/m/2D6/1A2 IC ₅₀ (μM)	>10/>10/>10	9.0/>10/>10	>10/>10/>10	>10/>10/>10

Increasing the polarity of the 6,5 heterobicyclic core lowers lipophilicity as reflected in measured LogD@ pH 7.4. 2C9/2C19 cytochrome P450 inhibition is decreased and cell proliferation potency maintained. Target EC₅₀ for inhibition of cell proliferation was ≤0.050 μM(HCT116) and ≤ 0.005 μM (A375).

Table 2.

Compound	G-868 5-imidazo[1,5-a] pyridine	G-606 8-imidazo[1,5-a] pyridine
HCT116 <u>prolif</u> IC ₅₀ (μM)	0.051	0.035
Mic (H/R/M/D/C) <u>pred</u> .CL <u>hep</u> mL/min/kg	14/38/64/12/30 M/M/H/M/M	15/40/75/23/38 M/M/H/H/H
Rat PK total CL(mL/min/kg), T _{1/2} (h), V _{ss} (L/kg), AUC(μM*hr) %F	13.2, 1.7 0.50, 20, >100	14.0, 0.9, 0.46, 6.0, 37
hERG (patch clamp) IC ₅₀ (μM)	4.4	2.1

Comparative potency, liver microsome stability(H= human,R= rat,M= mouse,D= dog, C= cyno,) rat PK and hERG patch clamp IC₅₀'s for **G-868** (representative of the 5-imidazo [1,5-a] pyridine class of MEKis) and **G-606** (representative of the 8-imidazo[1,5-a] pyridine class of MEKis). IV/PO dose= 1/5 mpk. AUC for **G-868** (IV/PO dose = 1/10 mpk) was normalized to a 5 mpk dose. IV/PO formulations = solution(60%PEG400/40%H₂O)/solution(60%PEG400/40%H₂O) for all compounds dosed.Dose volume = 5 mL/kg for all compounds dosed.

Liver microsomal stability ranges utilized for stable/moderate/labile designations; (CLhep) mL/min/kg; Stable (H/R/M)= <6.2/<17/27; Moderate (H/R/M)= 6.2-15/17-39/27-63; Labile (H/R/M)= >15/>39/>63.

Table 3.

HCT 116 cell <u>prolif</u> IC ₅₀ (μ M)	0.051	0.120
A375 cell <u>prolif</u> IC ₅₀ (μ M)	0.004	0.008
<u>clogP</u> / <u>clogD</u>	2.3/2.3	1.6/1.6
Predicted <u>pKa</u> (MOKA)	4.78	4.35
Predicted <u>pKa</u> (ACD)	5.84	3.34
<u>Measured pKa</u> (Sirius)	4.30	2.03
<u>LogD</u>	2.1	2.1
hERG patch clamp IC ₅₀	4.4 μ M	3.3 μ M

Comparative cell proliferation potencies, cLogD/cLogP, LogD@ pH 7.4, calculated and measured pKa's and hERG patchclamp IC₅₀'s for imidazo [1,5-a] pyridine **G-868** and imidazo [1,5-a] pyrazine **G-593** illustrates the value of obtaining *measured* logD's on a routine basis (RSD for LogD = $\pm$ 0.30). *For the imidazo [1,5-a] pyrazine core, the logD may exert a bigger influence on the hERG IC₅₀ than decreasing pKa.*

Table 4.

G# structure	Cell <u>prolif</u> IC ₅₀ (μ M) HCT116/A375	<u>clogP</u> <u>LogD</u>	TS pH 6.5, μ g/mL	Mic(H/R/M) (mL/min/kg)	PK(rat) <u>CL_p</u> / <u>CL</u> (free) (mL/min/kg), F(%),AUC(μ M*hr)	MDCK(A-B;B-A;B-A/A-B) 10 ⁻⁶ cm/s	<u>ppb</u> (H/R/M)(%)	<u>hERG</u> patch clamp IC ₅₀ (μ M)
 G-868	0.049/0.004	2.3 2.05	41 (cryst)	14/38/64 M/M/L	13.2/1320 100,20*	6.20/16.5/2.6	99.5/99/94	4.4
 G-606	0.035/0.002	2.3 2.05	110 (amorph)	15/40/75 M/M/L	14/636 6,37	20.4/14/0.7	98.5/97.8/95.1	2.1
 G-593	0.120/0.008	1.6 2.10	150 (amorph)	11/41/54 M/L/M	48/600 38,1.48	19.7/14/0.7	91/92/89	3.3
 G-327	0.052/0.005	2.1 2.2	48 (amorph)	10/44/56 M/L/M	44/800 15,0.61	ND	90/94.5/91	3.3
 G-479	0.107/0.007	0.95 1.1	12 (amorph)	8/19/29 S/M/M	12/92 65,9.2	7.9/8.7/1.3	86/87/87	14

Comparative potency, cLogP/LogD@ pH 7.4, thermodynamic solubility, liver microsome stability, rat PK, MDCK permeability and plasma protein binding (ppb, human, rat, mouse) for novel 6,5-heterobicyclic

MEKi's **G-868** and **G-606** (imidazo [1,5-*a*] pyridine class), and **G-593/G-327/G-479** (imidazo [1,5-*a*] pyrazine class). IV/PO dose= 1/5 mpk and 1/10 mpk **G-868**. *AUC normalized to a 5 mpk dose for **G-868**. IV/PO formulations = solution(60%PEG400/40%H₂O)/solution(60%PEG400/40%H₂O) for all compounds dosed. Dose volume = 5 mL/kg for all compounds dosed.

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Fig 1. The key interactions of biaryl aniline MEK inhibitors: crystal structure of MEK1 in complex with ATP (green) and **PD318088** (orange) (PDB code 1S9J). Figure 1 adapted with permission from Heald, R. A.; et al. *J. Med Chem* **2012**, 55, 4594. Copyright 2012 American Chemical Society.

Fig.2 As predicted based on “fit” to the MEK pharmacophore model, 6,5 heterobicyclic isobenzothiazole **G-155** exhibits increased cell proliferation potency versus its azabenzofuran comparator. HCT116 cell line was derived from malignant human colon cancer cells. A375 cell line was derived from malignant human melanoma cells.

Fig.3. Imidazo [1,5-*a*] pyridine binding mode. Left panel- co-crystal structure of a 5,6 azabenzofuran (2.8 Å resolution; PDB code 4U80) overlayed with a 6,5 imidazopyridine (2.7 Å resolution; PDB code 4U81). The 6,5 imidazopyridine N is suitably placed for an H-bond with Ser212 while maintaining the key hydroxamate and anilino pharmacophoric elements in a remarkably similar position as in **G-925**. Right panel- co-crystal structure of a 6,5 benzimidazole (**AZD6244**, 2.8 Å resolution; PDB code 4U7Z) overlayed with the same 6,5 imidazopyridine (PDB code 4U81). It is noteworthy that in the 6,5 imidazopyridine co-crystal structure the attachment point of the five membered ring heterocycle is shifted towards the B-ring versus its attachment point in **AZD6244**. Despite the shift, the imidazopyridine nitrogen is positioned to make a robust H-bond interaction to the Ser212 while maintaining the key hydroxamate and anilino pharmacophoric elements in a remarkably similar position as in **AZD6244**. These X-ray co-crystal structures support the hypothesis from modelling that novel 6,5 heterobicycles would result in MEK1's that would fit well in the MEK binding pocket and have a high probability for equivalent or improved potency versus the 5,6 azabenzofuran core.

Fig. 4. C8 Fluorine substitution improved CLp, T1/2, and oral exposure(PO dose 5mpk, rat) but increased CYP2C9 inhibition activity sevenfold. The more intense the red circle, the higher probability of metabolism (color gradient shown on bar on right and indicates low probability to high probability of metabolism taking place on circled carbon). The major metabolic site is indicated by a blue circle. For **G-868**, the MetaSite software identified C8 as the major metabolic site.

Fig. 5. Metasite analysis showing that a nitrogen incorporated at the C7 position removes two potential sites of metabolism. Note the major site of metabolism predicted by MetaSite is now the imidazo ring of the imidazo [1,5-*a*] pyridine core.

Fig 6. Imidazo [1,5-*a*] pyrazines **G-593/G-327/G-479**

Scheme 1.

Reagents and conditions²⁷(a) (i) 1.02 eq freshly prep'd LDA, THF, 1.0 eq **1**, -78°C, 2h (ii) CO₂ (xs), 41%

yield.(b)(i)2.0 eq.²⁸ , 3.0 eq LHMDS or LDA, THF, -78°C, 1h (ii) 1.0 eq **2**, THF, -78°C, 0.5h to rt, 63% yield.(c)

70% Toluene, 30%MeOH (0.06M), 0°C, 2.3 eq TMSCHN₂ (2.0M in hexane), warm to rt,1h, 71% yield, crude pdt.**4** used directly.(d) DMF²⁹, 1.0 eq **4** (0.16M),1.1eq Zn(CN)₂,0.125 eq Pd(PPh₃),microwave, 300 Watts, 150°C,25 min,78% yield.(e) **5**, glacial acetic acid (0.15M)³⁰, 10% Pd-C (20% by wt), H₂(1 atm, balloon),1.5h³¹,98% yield, crude pdt **6** used directly.(f) **6**, 75% formic acid/25% acetic anhydride³², rt 1.5h³³, 80% yield, crude product **7** used directly (g) **7**,anhydrous DCM(0.1M), 0°C, 2.0 eq iodine monochloride (1.0M sol'n in DCM) , 0°-rt, 1h³⁴, 98% yield, crude pdt.**8** used directly.(h) **8**,Toluene (0.025M, suspension), 4.2 eq POCl₃ , 95°C, 1h, SiO₂ purified (ISCO 35-100% EA/hex, followed by 0-30% MeOH/EA) 46% yield.(i) **9**,anhydr. 1,2 DCE (0.14M), 3.5 eq Sn(CH₃)₃OH, 85°C,1h, 98% yield^{35, 36}(j) **10**,

anhydr. DMF (0.2M), 1.04 equiv , or , or 1.05 eq HOBT, 4.8 eq 4-methylmorpholine, 1.05 eq EDCI, rt, 17h to 3d, 50% yield **G-327**³⁷, (k) anhydrous DCM/ MeOH (2:1), 1.5eq 4M HCL in 1,4 dioxane, rt, 1h(ii) 6.0 eq solid NaHCO₃, rt, 15 min, then Na₂SO₄ filter and purify on SiO₂(ISCO, 0-15% MeOH/DCM), 48%, 32% over coupling / deprotection steps **G-593/G-479**)³⁸

Scheme 2.

Preparation of hydroxamate directly from the methyl ester

Graphical Abstract